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Abstract
The hemochromatosis associated proteins HFE and Transferrin Receptor 2 (TFR2) have been shown to be important
for the proper regulation of hepcidin. A number of in vitro studies using transient overexpression systems have
suggested that an interaction between HFE and TFR2 is required for the regulation of hepcidin. This model of iron
sensing which centers upon the requirement for an interaction between HFE and TFR2 has recently been questioned
with in vivo studies in mice from our laboratory and others which suggest that Hfe and Tfr2 can regulate hepcidin
independently of each other. To re-examine the postulated interaction between Hfe and Tfr2 we developed a novel
expression system in which both proteins are stably co-expressed and used the proximity ligation assay to examine
the interactions between Hfe, Tfr1 and Tfr2 at a cellular level. We were able to detect the previously described
interaction between Hfe and Tfr1, and heterodimers between Tfr1 and Tfr2; however no interaction between Hfe and
Tfr2 was observed in our system. The results from this study indicate that Hfe and Tfr2 do not interact with each
other when they are stably expressed at similar levels. Furthermore, these results support in vivo studies which
suggest that Hfe and Tfr2 can independently regulate hepcidin.
Citation: Rishi G, Crampton EM, Wallace DF, Subramaniam VN (2013) In Situ Proximity Ligation Assays Indicate That Hemochromatosis Proteins Hfe and
Transferrin Receptor 2 (Tfr2) Do Not Interact. PLoS ONE 8(10): e77267. doi:10.1371/journal.pone.0077267
Editor: Matias A. Avila, University of Navarra School of Medicine and Center for Applied Medical Research (CIMA), Spain
Received May 5, 2013; Accepted September 2, 2013; Published October 14, 2013
Copyright: © 2013 Rishi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was Supported in part by a Project Grant (APP1031325) from the National Health and Medical Research Council (NHMRC) of
Australia to VNS. DFW is the recipient of the Gastroenterological Society of Australia Senior Research Fellowship. VNS is the recipient of an NHMRC
Senior Research Fellowship (1024672). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript. No additional external funding received for this study.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: Nathan.Subramaniam@qimr.edu.au
Introduction
Mutations in HFE and transferrin receptor 2 (TFR2) cause
hereditary hemochromatosis [1,2], which is characterized by an
inappropriate hepcidin (HAMP) expression relative to body iron
levels [3]. Hepcidin, a 25 amino acid antimicrobial peptide is a
negative regulator of iron stores; in response to increased iron
levels in the serum, hepatic hepcidin expression is increased
which then relays a signal to the sites of iron absorption
(duodenal enterocytes), recycling (macrophages) and storage
(hepatocytes) resulting in a decrease in the release of iron from
these tissues into the circulation.
HFE has been shown to interact with transferrin receptor 1
(TFR1) [4–6]. TFR1 is a ubiquitously expressed
transmembrane receptor responsible for the uptake of
transferrin (Tf) bound iron. One model of iron sensing suggests
that HFE and TFR2 are required for the proper regulation of
hepcidin synthesis. In this model when TFR1 bound to iron
saturated transferrin (holo-Tf) is internalized, HFE is released
and made available for binding to TFR2. The interaction of HFE
and TFR2 is then thought to initiate a signalling cascade to
regulate hepcidin. Initial studies using extracellular domains of
HFE and TFR2 failed to detect an interaction between the two
molecules [7]. Subsequent studies using transient
overexpression systems, however, identified an interaction
between HFE and TFR2 [8–10] and suggested that this
interaction is required for the regulation of hepcidin [10]. In a
recent study using the human hepatoma cell line (HuH-7) and
transient expression systems it was shown that HFE, TFR2
and hemojuvelin (HJV) form a complex on the membrane, and
the formation of this complex is required for the regulation of
hepcidin [11].
In a recent study using transgenic mice expressing myc-
tagged Hfe, no interaction was detected between the myc-
tagged Hfe and Tfr2 [12]. In addition, hepatocyte specific
expression of myc-tagged Hfe reduced iron stores and induced
hepcidin synthesis in Tfr2 mutant mice. These results suggest
that Tfr2 is not required for Hfe-mediated hepcidin synthesis
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[12]. In a time-course study in subjects with HFE and TFR2
mutations, hepcidin levels were measured after administration
of oral iron [13]. It was shown that the patients with mutations
in TFR2 did not respond to increases in transferrin saturation
whereas there was a minimal hepcidin response in patients
with HFE mutations under the same conditions [13]. The
hepcidin response in patients with HFE mutations suggests
that TFR2 can regulate hepcidin independently of HFE.
The comparison of Hfe-/-, Tfr2-/- and double knockout mice
(Hfe-/- Tfr2-/-) [14] shows that there is a gradation in hepatic iron
overload, with the hepatic iron concentration and serum
transferrin saturation increasing from WT<Hfe-/-<Tfr2-/-< Hfe-/-
Tfr2-/-. It was also shown that there is a gradation in the levels
of hepatic hepcidin relative to body iron stores in the following
order WT>Hfe-/->Tfr2-/->Hfe-/- Tfr2-/-, indicating that both Hfe and
Tfr2 contribute to the sensing of body iron stores. In agreement
with this, subjects with mutations in both TFR2 and HFE
present with a more severe form of disease compared to
patients with either TFR2 or HFE mutations alone, with a
phenotype similar to juvenile hemochromatosis [15]. These
observations suggest that HFE and TFR2 do not need to
interact with each other to mediate a hepcidin response,
prompting us to re-examine the postulated interaction between
Hfe and Tfr2.
To circumvent potential artefact issues associated with
transient overexpression we used a novel co-expression
system, in which FLAG-tagged Hfe and myc-tagged Tfr2 are
stably expressed under the same promoter. Importantly, the
relative levels of Hfe and Tfr2 are similar, unlike the previous
studies where either of the two proteins was transiently over
expressed. The expression and cellular localisation of Hfe, Tfr1
and Tfr2 were determined by immunoblotting and
immunofluorescence. The interactions between Hfe, Tfr1 and
Tfr2 were examined at a cellular level by the use of a recently
developed commercial assay (DuolinkTM) based on the principle
of proximity ligation. Our results show that stably co-expressed
Hfe and Tfr2 do not interact. We were able to identify
previously reported interactions between Hfe and Tfr1 and the
formation of heterodimers between Tfr1 and Tfr2. These results
were confirmed using the conventional co-immunoprecipitation
approach.
Materials and Methods
a: Generation of the plasmids and stable expression
The mouse Hfe (mHfe) coding sequence minus the signal
peptide was amplified from mouse liver cDNA using the
following primers: FP2-mHfe-Mlu
CCGACGCGTGCACTGCCACCGCGT and RP2-mHfe-Mlu
CCGACGCGTTCACTCACAGTCTGT and cloned into the MluI
site of the pEFIRES-FLAG-S plasmid to create a bicistronic
construct containing the IL-3 signal peptide fused to amino-
terminally FLAG-tagged mHfe with the puromycin resistance
gene (pac) following an internal ribosome entry site (IRES).
This construct, pEFIRES-FLAG-mHfe and another bicistronic
construct encoding amino-terminally double myc-tagged mouse
transferrin receptor 2 (mTfr2), pEFIRES-NH2-Dmyc-mTfr2 or
pEFIRES-NH2-Dmyc-mTfr2Y245X (construction described in [16]
were used to create a tricistronic construct encoding the mHfe,
mTfr2 (wild type or mutant) and pac genes each separated by
an IRES sequence. The FLAG-tagged mHfe gene was PCR
amplified along with the downstream IRES sequence from the
pEFIRES-FLAG-mHfe plasmid using the following primers: 5’
IL-3-SP-IRES-NheI TAGGCTAGCACAATGGTTCTTG and 3’
IRES-NheI CATGCTAGCATCGTGTTTTTCAAAGGA and
cloned into the NheI site of the pEFIRES-NH2-Dmyc-mTfr2
plasmid upstream of the double-myc-tagged mTfr2 gene.
b: Transfections
The mouse hepatoma cell line Hepa 1-6 was obtained from
ATCC (CRL-1830; American Type Culture Collection,
Manassas, VA) and cultured in DMEM with 10% fetal calf
serum (FCS) in 25 cm2 flasks. Transfections were performed
using Lipofectamine 2000 reagent according to the
manufacturer’s instructions (Invitrogen, Mulgrave, Victoria,
Australia). Plasmid DNA (10 μg) was complexed with 25 μl
Lipofectamine 2000 reagent. The complexes were added to the
cells and incubated overnight. Stably transfected cell lines were
isolated by selection with 5 ug/ml puromycin for 1 day and were
then stably maintained in 1 ug/ml of the antibiotic. Expression
of transfectants was conﬁrmed by immunoblot analysis and
immunofluorescence analysis. In the experiments involving
treatment of the cells, Hepa1-6 cells expressing wild type Hfe
and Tfr2 were incubated with either apo-transferrin (apo-Tf) or
holo-transferrin (holo-Tf) (Sigma, Sydney, NSW, Australia)
(2mg/ml) for 24 hours. The apo and holo-Tf was prepared in
DMEM with 10% FCS and 1µg/ml puromycin.
c: Western blotting
Samples were separated by 12% SDS-PAGE, transferred
onto Hybond-C membrane, and blocked in 10% skim milk
powder-0.1% Tween 20 in TBS (Tris-buffered saline; blocking
buffer) at room temperature for 2 hours and incubated with
rabbit anti-Tfr2 [17] (1µg/ml) for 2 hours at room temperature or
mouse anti-FLAG M2 (1:2000; Sigma) in blocking buffer
overnight at 4°C. Blots were washed extensively with 0.1%
Tween 20 in TBS, and then incubated with anti-rabbit or anti-
mouse IgG horseradish peroxidise (Invitrogen) for 1 h at room
temperature. Lumina Forte Millipore chemiluminescent
substrate (Millipore, Kilsyth, Victoria, Australia) was applied for
5 min to the blot, which was then exposed to ﬁlm (Fujiﬁlm,
Brookvale, NSW, Australia). The blots were stripped with 50
mM Tris HCl pH 6.8, 1% SDS, 0.7% ß-mercaptoethanol at
50°C for 30 min, and then washed with 0.1% Tween 20 in TBS
and blocked before incubating with rabbit anti-actin (Sigma)
(1:3000) or mouse anti-Tfr1 (Invitrogen) (1:1500) in blocking
buffer, washed with 0.1% Tween 20 in TBS, incubated with
anti-mouse or anti-rabbit horseradish peroxidise (for 1 h at
room temperature and then incubated with Lumina Forte
Millipore chemiluminescent substrate (Millipore) for 5 min. The
blot was then exposed to ﬁlm. For the immunoblots for
immunoprecipitation experiments, anti-mouse or anti-rabbit
light chain IgG secondary antibodies (Jackson
Immunoresearch Inc, PA, USA) were used at 1:5000 for 1 hour
at room temperature.
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d: Immunofluorescence and Confocal Microscopy
Cells were seeded on collagen coated glass coverslips and
grown to a confluence of 75-80%. After washing with PBSCM
(PBS, 1mMCaCl2, 1mM MgCl2) three times the cells were fixed
with cold 3% paraformaldehyde (PFA) for 15 minutes at room
temperature (RT). The fixed cells were then washed with
50mM NH4Cl to quench the PFA followed by a PBSCM wash
and permeabilized with 0.1% saponin in PBSCM for 15 minutes
at RT and incubated with primary antibodies: rabbit anti-Tfr2
(1µg/ml), mouse anti-Tfr1 (1:500), mouse anti-FLAG M2
(1:1000) or rabbit anti-Tfr1 (Abcam, Cambridge, UK) (1:100)
diluted in fluorescence dilution buffer (FDB) (5% fetal calf
serum, 5% normal donkey serum, 2% bovine serum albumin in
PBSCM, pH7.6) for 2 hours at RT. After washing 3 times in
0.1% saponin/PBSCM the cells were incubated with donkey
anti-mouse Alexa488 and donkey anti-rabbit Alexa594
(Invitrogen) for 1 hour at RT. After washing with 0.1% saponin/
PBSCM the cover slips were then mounted using Prolong Gold
anti-fade with DAPI (Invitrogen). The imaging and visualisation
of the fluorescently stained cells was performed using the
Nikon C2 confocal microscope using a 63X oil immersion
objective. We used NIS Elements software for the acquisition
and processing of the images.
e: Co-Immunoprecipitation (Co-IP)
The cells were cultured to confluence in 25 cm2 flasks and
then lysed in an extraction buffer (200mM Tris pH8.0, 100mM
NaCl, 1mM EDTA, 10% glycerol, 1mM sodium orthovanadate,
1mM sodium fluoride, 1mM sodium pyrophosphate, 2mM
Phenylmethylsufonylfluoride, DNAase (1:1000), Protease
Inhibitor Cocktail (1:100; Sigma) and 20 % NP 40). To perform
a Co-IP with Hfe, anti-DYKDDDDK beads were used (Clontech
Laboratories Inc. CA, USA). All the other antibodies used for
immunoprecipitation were crosslinked with protein A/G beads
(Roche, Dee Why, NSW, Australia) using dimethyl
pimelimidate (Sigma). After pre-clearing with a mixture of anti-
rabbit and anti-mouse IgG agarose (Sigma), 1mg of protein
was incubated with anti-DYKDDDDK, anti-Tfr2, anti-rabbit IgG
or anti-mouse IgG beads overnight at 4°C. The beads were
then washed with 0.5% NP-40, 150mM sodium chloride, 50mM
Tris pH 8.0, 5mM EDTA (NET) buffer without the detergent and
resuspended in 1X sample buffer containing 5 % β-
mercaptoethanol and stored at -20°C till further use.
f: Proximity Ligation Assays (PLA, ‘In Cell’ Co-IP)
The mouse/rabbit red starter Duolink kit (Olink, Uppsala,
Sweden) was used for this experiment. Hepa1-6 cells stably
expressing FLAG-tagged Hfe and myc-tagged Tfr2 were
seeded at 15x103 cells per well in a 16-well chamber slide
(Thermofisher, Scoresby, Victoria, Australia). The cells were
fixed and permeabilized as described above for
immunofluorescence studies. After permeabilization the cells
were incubated in the blocking buffer (provided with the kit)
overnight at 37°C in a humidified chamber. The following day
the cells were incubated with the primary antibodies diluted in
the antibody diluents for 2 hours at room temperature (used at
the same concentrations as in immunofluorescence studies).
For the rest of the protocol the manufacturer’s instructions were
followed. Briefly, the cells were washed in Buffer A (supplied
with the kit) 3 times for 15 minutes and incubated with the PLA
probes for one hour at 37°C in a humid chamber. This was
followed by a 10 minute wash and a 5 minute wash in Buffer A.
The ligation reaction was carried out at 37°C for one hour in a
humid chamber followed by a 10 and 5 minute wash in Buffer
A. The cells were then incubated with the amplification mix for
two hours at 37°C in a darkened humidified chamber. After
washing with 1x Buffer B (supplied with the kit) for 10 minutes
followed by a 1 minute wash with 0.01X buffer B the cells were
mounted using the mounting media supplied with the kit.
Results
a: Stable co-expression of Hfe and Tfr2 in Hepa 1-6
cells does not affect their localization
In order to determine the interactions between Hfe, Tfr1 and
Tfr2, Hepa 1-6 cells stably expressing N-terminal myc-tagged
wild type (WT) Tfr2 or Y245X (YX) mutant Tfr2 alone or with
FLAG-tagged WT Hfe were utilised. The Y245X Tfr2 mutant
used here has been characterised previously [18] and in
humans the corresponding truncation mutation, Y250X, is
associated with hereditary hemochromatosis (HH) type III [1].
Figure 1 shows the relative expression of Hfe, Tfr1 and Tfr2 in
untransfected and transfected cells. We observed two bands
for Tfr2 which could be due to a glycosylated form of the
protein [19]. Figure 1B shows the truncated Tfr2Y245X protein at
approximately 40kDa. Tfr1 is endogenously expressed in
Hepa1-6 cells.
Overexpression of tagged proteins may lead to their
aggregation [20] or mislocalization [21,22] thus affecting their
function. In order to determine whether stable co-expression of
Hfe and Tfr2 in Hepa1-6 cells affects their localization, we
examined the localization patterns of these proteins in cells
expressing either myc-tagged WT Tfr2 or FLAG-tagged WT
Hfe singly or cells co-expressing both Hfe and Tfr2. The
confocal images in Figures 2, 3, 4 and 5 show that both Hfe
and Tfr2 have a similar localization whether expressed singly
or together. This indicates that the co-expression of Hfe and
Tfr2 does not affect their localization and function. FLAG-
tagged Hfe, endogenous Tfr1 and myc tagged Tfr2 localized
mostly intracellularly but expression of all three proteins on the
plasma membrane was also detected as shown in Figures 2, 3,
4, and 5.
Co-localization of two proteins suggests that they are present
in the same subcellular compartments. In order to examine the
co-localization between Hfe, Tfr1 and Tfr2 a double
immunofluorescence experiment was performed. Panels 3C
and 3D show that Tfr1 partially co-localizes with WT Tfr2. We
had shown earlier that Tfr2Y245X has a defect in trafficking and is
retained in the endoplasmic reticulum [16]; panel 3F shows that
there is a change in the localization of the truncated protein as
compared to 3B. The change in localization of Tfr2Y245X leads to
a decrease in co-localization of Tfr1 and Tfr2 as seen in 3H.
The co-localization signal could be observed intracellularly as
well as on the surface of the cells.
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In the cells expressing Hfe and WT Tfr2 and Tfr2Y245X, we
observed a significant co-localization between Hfe and Tfr1
(Panel 4 C and D).
It was reported previously that HFE and TFR2 co-localize
intracellularly in the crypt cells of the duodenum [23]. In our co-
expression system we observed nominal co-localization
between Hfe and WT Tfr2 in punctuate intracellular vesicles
(Panel 5 C and D). The minimal co-localization of the two
proteins suggests that they could transiently co-exist in the
Figure 1.  Analysis of expression of Hfe, Tfr1 and Tfr2 in transfected Hepa 1-6 cells.  Hepa1-6 cells stably co-expressing
FLAG-tagged Hfe and myc-tagged Tfr2 (WT), or truncated Tfr2 (YX) were analysed by Western blotting. (A) Immunoblot showing
the relative expression levels of Tfr1, Tfr2 and Hfe in untransfected Hepa1-6 cells (UT), Hepa1-6 cells transfected with a vector to
co-express Hfe and WT Tfr2. (B) Immunoblot showing the expression of FLAG-tagged Hfe, Tfr1 and truncated YX Tfr2 (~45kD). β-
actin was used as a loading control in all the immunoblots.
doi: 10.1371/journal.pone.0077267.g001
Figure 2.  Co-localization of Tfr1 with Hfe and Tfr2.  Confocal microscopy analysis of Tfr1, Tfr2 and Hfe in Hepa1-6 cells
expressing either (A, B and C) myc-tagged Tfr2 alone or (E, F and G) FLAG-tagged Hfe alone. The transfected proteins were co-
localized with endogenous Tfr1. Images were obtained using a Nikon C2 confocal microscope. The insets D and H show the co-
localization represented by arrows. Scale bar= 20µm.
doi: 10.1371/journal.pone.0077267.g002
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same sub-cellular compartment and hence could be involved in
an interaction.
b: In situ proximity ligation assay shows that Hfe and
Tfr2 do not interact
Co-immunoprecipitation (Co-IP) is a standard method to
determine whether two proteins of interest form a complex;
however sometimes this technique fails to detect weak or
transient interactions [24]. Co-IP involves lysis of the cells, this
could bring proteins which are usually in different subcellular
compartments together and result in false positive detection of
an interaction [24]. The nominal co-localization observed
between Hfe and Tfr2 in Figure 5 suggests that a small
proportion of molecules may be involved in an interaction. A
recently developed commercial assay (Duolink) based on
proximity ligation (PLA) overcomes these limitations [25]. The
advantage of PLA over conventional Co-IP is that it identifies
individual interactions between two proteins in their native form
that may be weak or transient in nature. The assay results in a
fluorescent signal in the form of a spot when the two proteins of
interest are closer than 40nm. To determine the interactions
between Hfe, Tfr1 and Tfr2 using the PLA we used Hepa1-6
cells stably expressing Hfe and Tfr2.
The specificity of the assay was tested using a single
antibody directed against FLAG, Tfr1 and Tfr2, these also
served as negative controls (Figure 6 A, B, C, D). The absence
of any spots indicates that the assay is specific with minimal
non-specific proximity signals. The PLA was able to identify
Tfr1 and Tfr2 as partners in Hepa1-6 cells, as indicated by the
red dots in the panels (Figure 7 A); each red dot represents a
molecular interaction between the two proteins of interest. This
is in agreement with previously published data [26] where it
was shown that Tfr1 and Tfr2 can form heterodimers. Similarly,
Hfe and Tfr1 were also identified as proximity partners (Figure
7 B). The absence of any PLA signal in panel 7 C indicates that
Hfe and Tfr2 do not interact in the Hepa 1-6 cells co-expressing
Hfe and Tfr2.
The proposed iron sensing model suggests that in the
presence of holo-Tf, HFE is released from TFR1 and made
available to interact with TFR2. We did not observe an
interaction between Hfe and Tfr2, suggesting that under normal
conditions there is little or no interaction between Hfe and Tfr2.
In order to determine the dynamics of Hfe and Tfr2 interaction
in the presence of holo-Tf, we treated the cells expressing WT
Hfe and Tfr2 with 2 mg/ml of holo-Tf or apo-Tf (as previously
described [8]) for 24 hours; PLA was performed on these
treated cells. The panels 7 D-F represent the cells treated with
apo-Tf and panels 7 G-I represent the cells treated with holo-
Figure 3.  Co-localization of Tfr1 and Tfr2 in Hepa1-6 cells.  Confocal microscopy analysis of Hepa1-6 cells stably co-expressing
Hfe and either Tfr2 (WT) or truncated Tfr2YX (YX). The localization of Tfr1 (A, E) appears to be endosomal as previously shown, the
wild type Tfr2 (B) also localizes to an endosomal compartment and to the plasma membrane, represented by white arrows whereas
the Tfr2YX (F) appears to accumulate in ER (as previously described by our laboratory, [16]. Tfr2YX does not co-localize with Tfr1 (H).
Images were obtained using a Nikon C2 confocal microscope. Scale bar =20µm.
doi: 10.1371/journal.pone.0077267.g003
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Tf. The results show that in the presence of apo- or holo-Tf,
Tfr1 and Tfr2 form heterodimers (7 D and G, respectively), and
Hfe and Tfr1 interact (7 E and H, respectively). The holo-Tf
treatment resulted in a decrease in the number of red spots per
nuclei (panel 7 G and H). It has been shown that in the
presence of holo-Tf Tfr1 is internalized and the interaction
between Hfe and Tfr1 decreases [10]. The absence of any
proximity signals in the panels 7 F and I indicates that Hfe and
Tfr2 do not interact in the presence of either apo- or holo-Tf in
Hepa 1-6 cells. These results are contrary to the previously
published data which suggests that in the presence of holo-Tf,
the interaction between Hfe and Tfr2 increases.
c: Co-Immunoprecipitation experiments confirm the
absence of interactions between Hfe and Tfr2
Since we did not detect any interaction between Hfe and Tfr2
using the highly sensitive PLA, we hypothesized that any
interaction could be transient. To ensure that the weak and
transient interactions were stabilized the cells were treated with
Bissulphosuccinimidyl suberate (BS3) a surface crosslinker for
30 minutes at 4 °C before harvesting the cells for protein
extraction. The lysates from Hepa 1-6 cells stably expressing
Hfe and Tfr2 were used to precipitate proteins which form
complexes with either Hfe (FLAG) or Tfr2. Rabbit IgG and
mouse IgG were used as controls to detect any non-specific
binding. Figure 8 A shows that Tfr1 can form a complex with
Hfe and Tfr2 as previously characterized. These results were
indicative that both the expressed proteins were functional. A
small amount of non-specific binding of Tfr1 can be detected in
the lanes representing rabbit IgG and mouse IgG IPs. Figure 8
B indicates that neither Hfe nor Tfr2 are present in a protein
complex with each other in the Hepa 1-6 cells. The absence of
any bands in the IgG lanes indicates that the assay is specific.
In a previous study involving a domain swap of Tfr1 and Tfr2
[8] it was shown that amino acid residues 104-249 of TFR2 are
sufficient for it to interact with HFE. We performed a Co-IP
experiment with anti-FLAG and anti-Tfr2 using lysates from
cells expressing Hfe and Tfr2Y245X; Figure 8 C shows that the
truncated form of Tfr2 which contains only the first 244 amino
acids of Tfr2 does not exist in a complex with FLAG-tagged
Hfe.
A Co-IP performed on the lysates of cells treated with apo-
and holo-Tf shows that Hfe and Tfr2 do not interact with each
other in either of the conditions (8 D). These results are
contrary to the previously published data which suggested that
in the presence of holo-Tf, Hfe and Tfr2 form a complex.
Discussion
Previous studies using transient overexpression systems
showed that HFE and TFR2 interact [8–10] and that this
interaction is important for HFE and TFR2 mediated regulation
of hepcidin [10,11]. Some recent studies have suggested that
HFE and TFR2 can independently regulate hepcidin and could
Figure 4.  Co-localization of Hfe and Tfr1.  Confocal analysis was performed to determine the co-localization of Hfe and Tfr1 in
Hepa1-6 cells stably co-expressing Hfe and either Tfr2 (WT) or truncated Tfr2YX (YX). Hfe (A and E) and Tfr1 (B, and F) co-localize
in endosomal compartments and on the membrane (represented by white arrows) in the cells stably co-expressing Hfe and WT Tfr2
(C and G) or YX Tfr2 (D and H). The images were obtained using a Nikon C2 confocal microscope. Scale bar=20µm.
doi: 10.1371/journal.pone.0077267.g004
Interaction between Hemochromatosis Proteins
PLOS ONE | www.plosone.org 6 October 2013 | Volume 8 | Issue 10 | e77267
be acting in parallel to each other rather than synergistically
[12–14].
To examine putative interactions between these proteins we
developed a novel expression system where both Hfe and Tfr2
are stably co-expressed using a tricistronic vector. Using
Figure 5.  Co-localization between Hfe and Tfr2.  Confocal microscopy analysis of Hepa1-6 cells stably co-expressing Hfe and
either Tfr2 (WT) or truncated Tfr2YX (YX) reveals that Hfe and Tfr2 do not co-localize significantly in cells stably co-expressing Hfe
and WT Tfr2 (C and D) or truncated YX Tfr2 ( G and H). There is a small degree of overlap seen in some structures in WT (D)
suggesting that Hfe and Tfr2 could be transiently present in the same sub-cellular structures. Images were acquired using Nikon C2
confocal microscope. Scale bar=20µm.
doi: 10.1371/journal.pone.0077267.g005
Figure 6.  Specificity of PLA for transfected Hepa 1-6 cells.  PLA was performed on Hepa1-6 cells stably co-expressing Hfe and
Tfr2 (WT).The non-specific signal was examined by incubating Hepa1-6 cells with single antibodies directed against FLAG (A), Tfr1
(mouse) (B), Tfr1 (Rabbit) (C), or Tfr2 (D). The absence of any proximity signal indicates that the assay is specific. Tfr1 (mouse) –
anti Tfr1 antibody raised in mouse, Tfr1 (Rabbit)- anti Tfr1 antibody raised in rabbit.
doi: 10.1371/journal.pone.0077267.g006
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immunofluorescence and Co-IP we were able to show that a
stable co-expression of Hfe and Tfr2 does not affect their
localization or function. We observed partial co-localization
between Tfr1 and Hfe, and Tfr1 and Tfr2 suggesting that these
proteins could be present in similar subcellular compartments
and hence could interact or form a complex. As previously
described, we again showed that the YX mutant of Tfr2 (which
contains only the first 244 amino acids of the protein) is
retained in the endoplasmic reticulum [16].
Figure 7.  PLA shows that Hfe and Tfr2 do not interact.  PLA was performed on Hepa1-6 cells stably co-expressing Hfe and Tfr2
(WT). Previously characterized interactions between Tfr1 and Tfr2 (A, D and G) and Hfe and Tfr1 (B, E and H) were detected. Hfe
and Tfr2 do not interact in untreated WT cells (C) or cells treated with apo-Tf (F) or holo-Tf (I). The arrows indicate the red spots
representative of the interactions between the proteins of interest, each red spot is equivalent of one molecular interaction. Images
were acquired using a Nikon C1 confocal microscope. Scale Bar=20µm. Apo-Tf cells were cultured in 2mg/ml of apo-Tf for 24 hours
and Holo-Tf cells were cultured in 2mg/ml of holo-Tf for 24 hours. FLAG+ Tfr1 represents the experiment where antibodies against
FLAG tagged Hfe and Tfr1 (raised in Rabbit) were used, Similarly Tfr1+Tfr2 represents the experiment where Tfr1 (raised in mouse)
and Tfr2 were used, and FLAG+Tfr2 represents the experiment where antibodies against FLAG tagged Hfe and Tfr2 were used.
doi: 10.1371/journal.pone.0077267.g007
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The co-localization studies indicated some overlap between
Hfe and Tfr2 in the cells expressing WT Hfe and Tfr2; hence
we hypothesized that they could be involved in transient or
weak interactions which sometimes cannot be detected using
Co-IP. The PLA is a sensitive technique which can be used to
visualize weak and transient interactions at a cellular and
molecular level. A signal is observed only if the two proteins of
interest are in close proximity with each other (40nm or less).
This is the first report describing the interactions between Hfe-
Tfr1 and Tfr1-Tfr2 at a cellular level. The images in Figure 7
suggest that there are more Tfr1-Tfr2 dimerisation events as
compared to interactions between Hfe and Tfr1. Although
previous studies have suggested that HFE and TFR2 interact,
we did not detect any interactions between Hfe and Tfr2 in our
Figure 8.  Co-immunoprecipitation experiments reveal that Hfe and Tfr2 do not form a complex.  Hepa1-6 cells stably co-
expressing FLAG-tagged Hfe and myc-tagged Tfr2 (WT) were used to determine interactions between Hfe, Tfr1 and Tfr2. (A) Tfr1
interacts with Hfe and Tfr2. A Co-IP with IgG rabbit and mouse antibody shows some non-specific binding with Tfr1. (B) Co-
immunoprecipitation with anti-DYKDDDDK beads and anti-Tfr2 antibody reveals that Hfe and Tfr2 do not form a complex with each
other. (C) Hfe and Tfr2 do not interact with each in Hepa 1-6 cells co-expressing FLAG-tagged Hfe and myc-tagged Tfr2YX. (D) WT
cells were cultured in 2mg/ml apo- or holo-Tf for 24 hours and a Co-IP was performed with anti DYKDDDDK beads and anti Tfr2
antibody. Hfe and Tfr2 do not interact with each other in the presence of either apo- or holo-Tf. SM - starting material or input, IgG M
- IgG mouse, IgG Rb - IgG Rabbit, Apo-Tf- apotransferrin, Holo-Tf- holotransferrin.
doi: 10.1371/journal.pone.0077267.g008
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stable expression system when using either the highly sensitive
PLA or Co-IP. It was shown earlier that a chimera of TFR1 and
TFR2 consisting of TFR2104-250 is able to interact with HFE [8]. A
Co-IP experiment performed using cell lysates from our co-
expression system shows that Tfr2YX and Hfe do not form a
complex with each other.
The iron sensing model suggests that in the presence of
holo-Tf the interaction between HFE and TFR2 increases and
this interaction signals a cascade of events which leads to HFE
and TFR2 mediated regulation of hepcidin. We treated the
Hepa1-6 cells stably co-expressing Hfe and WT Tfr2 with apo-
or holo-Tf in order to determine whether Hfe and Tfr2 interact in
our co-expression system. The results suggest that Hfe and
Tfr2 do not form a complex with each other when they are
stably co-expressed. The results from our experiments and
recent studies [12,14] indicate that Hfe and Tfr2 can act
independently and do not need to interact as earlier studies
had suggested. Although previous in-vitro studies using
transient expression systems have been able to detect the
interactions [8–10], our results probably differ because of a
stable co-expression of the two proteins. This is supported by a
recent in-vivo study showing that mice expressing transgenic
Hfe could regulate hepcidin independently of Tfr2 [12]. The
authors did not observe any interaction between Hfe and Tfr2
and had suggested that some inhibitor in the tissue lysate
could be responsible for degrading or inhibiting the complex.
However, our results indicate that even in pure cell populations
expressing the two proteins, Hfe and Tfr2 do not form a
complex. One of the drawbacks of our system is that unlike
some previously published studies [10] we could not measure
the regulation of hepcidin in the presence of holo-Tf.
In addition to this, a large scale immunoprecipitation was
performed in our laboratory using a previously characterized,
highly specific Tfr2 antibody generated in the laboratory [17]
and total liver homogenates (results not shown), to identify the
protein partners that could interact with Tfr2. A mass
spectrometric analysis of the immunoprecipitated complexes
did not reveal Hfe as a binding partner of Tfr2. In the same
experiment we were able to identify Tfr1 as a binding partner
for Tfr2.
The results from our studies combined with that of previous
studies suggest independent roles for Hfe and Tfr2 in
regulating hepcidin. Future studies should be directed at
dissecting these roles and identifying whether Hfe and Tfr2 are
a part of a single signalling cascade, or if they act in parallel to
each other to regulate hepcidin.
Author Contributions
Conceived and designed the experiments: GR EC DFW VNS.
Performed the experiments: GR EC DFW. Analyzed the data:
GR EC DFW VNS. Contributed reagents/materials/analysis
tools: VNS. Wrote the manuscript: GR DFW VNS.
References
1. Camaschella C, Roetto A, Calì A, De Gobbi M, Garozzo G et al. (2000)
The gene TFR2 is mutated in a new type of haemochromatosis
mapping to 7q22. Nat Genet 25: 14-15. doi:10.1038/75534. PubMed:
10802645.
2. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA et al. (1996)
A novel MHC class I-like gene is mutated in patients with hereditary
haemochromatosis. Nat Genet 13: 399-408. doi:10.1038/ng0896-399.
PubMed: 8696333.
3. Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C (2005)
Hepcidin is decreased in TFR2 hemochromatosis. Blood 105:
1803-1806. doi:10.1182/blood-2004-08-3042. PubMed: 15486069.
4. Feder JN, Penny DM, Irrinki A, Lee VK, Lebrón JA et al. (1998) The
hemochromatosis gene product complexes with the transferrin receptor
and lowers its affinity for ligand binding. Proc Natl Acad Sci U S A 95:
1472-1477. doi:10.1073/pnas.95.4.1472. PubMed: 9465039.
5. Lebrón JA, Bennett MJ, Vaughn DE, Chirino AJ, Snow PM et al. (1998)
Crystal structure of the hemochromatosis protein HFE and
characterization of its interaction with transferrin receptor. Cell 93:
111-123. doi:10.1016/S0092-8674(00)81151-4. PubMed: 9546397.
6. Parkkila S, Waheed A, Britton RS, Bacon BR, Zhou XY et al. (1997)
Association of the transferrin receptor in human placenta with HFE, the
protein defective in hereditary hemochromatosis. Proc Natl Acad Sci U
S A 94: 13198-13202. doi:10.1073/pnas.94.24.13198. PubMed:
9371823.
7. West AP Jr., Bennett MJ, Sellers VM, Andrews NC, Enns CA et al.
(2000) Comparison of the interactions of transferrin receptor and
transferrin receptor 2 with transferrin and the hereditary
hemochromatosis protein HFE. J Biol Chem 275: 38135-38138. doi:
10.1074/jbc.C000664200. PubMed: 11027676.
8. Chen J, Chloupková M, Gao J, Chapman-Arvedson TL, Enns CA
(2007) HFE modulates transferrin receptor 2 levels in hepatoma cells
via interactions that differ from transferrin receptor 1-HFE interactions.
J Biol Chem 282: 36862-36870. doi:10.1074/jbc.M706720200.
PubMed: 17956864.
9. Goswami T, Andrews NC (2006) Hereditary hemochromatosis protein,
HFE, interaction with transferrin receptor 2 suggests a molecular
mechanism for mammalian iron sensing. J Biol Chem 281:
28494-28498. doi:10.1074/jbc.C600197200. PubMed: 16893896.
10. Gao J, Chen J, Kramer M, Tsukamoto H, Zhang AS et al. (2009)
Interaction of the hereditary hemochromatosis protein HFE with
transferrin receptor 2 is required for transferrin-induced hepcidin
expression. Cell Metab 9: 217-227. doi:10.1016/j.cmet.2009.01.010.
PubMed: 19254567.
11. D'Alessio F, Hentze MW, Muckenthaler MU (2012) The
hemochromatosis proteins HFE, TfR2, and HJV form a membrane-
associated protein complex for hepcidin regulation. J Hepatol 57:
1052-1060. doi:10.1016/j.jhep.2012.06.015. PubMed: 22728873.
12. Schmidt PJ, Fleming MD (2012) Transgenic HFE-dependent induction
of hepcidin in mice does not require transferrin receptor-2. Am J
Hematol 87: 588-595. doi:10.1002/ajh.23173. PubMed: 22460705.
13. Girelli D, Trombini P, Busti F, Campostrini N, Sandri M et al. (2011) A
time course of hepcidin response to iron challenge in patients with HFE
and TFR2 hemochromatosis. Haematologica 96: 500-506. doi:10.3324/
haematol.2010.033449. PubMed: 21173098.
14. Wallace DF, Summerville L, Crampton EM, Frazer DM, Anderson GJ et
al. (2009) Combined deletion of Hfe and transferrin receptor 2 in mice
leads to marked dysregulation of hepcidin and iron overload.
Hepatology 50: 1992-2000. doi:10.1002/hep.23198. PubMed:
19824072.
15. Pietrangelo A, Caleffi A, Henrion J, Ferrara F, Corradini E et al. (2005)
Juvenile hemochromatosis associated with pathogenic mutations of
adult hemochromatosis genes. Gastroenterology 128: 470-479. doi:
10.1053/j.gastro.2004.11.057. PubMed: 15685557.
16. Wallace DF, Summerville L, Crampton EM, Subramaniam VN (2008)
Defective trafficking and localization of mutated transferrin receptor 2:
implications for type 3 hereditary hemochromatosis. Am J Physiol Cell
Physiol 294: C383-C390. PubMed: 18094142.
17. Wallace DF, Summerville L, Lusby PE, Subramaniam VN (2005) First
phenotypic description of transferrin receptor 2 knockout mouse, and
the role of hepcidin. Gut 54: 980-986. doi:10.1136/gut.2004.062018.
PubMed: 15951546.
18. Fleming RE, Ahmann JR, Migas MC, Waheed A, Koeffler HP et al.
(2002) Targeted mutagenesis of the murine transferrin receptor-2 gene
produces hemochromatosis. Proc Natl Acad Sci U S A 99:
10653-10658. doi:10.1073/pnas.162360699. PubMed: 12134060.
19. Kawabata H, Germain RS, Vuong PT, Nakamaki T, Said JW et al.
(2000) Transferrin receptor 2-alpha supports cell growth both in iron-
Interaction between Hemochromatosis Proteins
PLOS ONE | www.plosone.org 10 October 2013 | Volume 8 | Issue 10 | e77267
chelated cultured cells and in vivo. J Biol Chem 275: 16618-16625. doi:
10.1074/jbc.M908846199. PubMed: 10748106.
20. Hu Y, Chuang JZ, Xu K, McGraw TG, Sung CH (2002) SARA, a FYVE
domain protein, affects Rab5-mediated endocytosis. J Cell Sci 115:
4755-4763. doi:10.1242/jcs.00177. PubMed: 12432064.
21. Nantel A, Huber M, Thomas DY (1999) Localization of endogenous
Grb10 to the mitochondria and its interaction with the mitochondrial-
associated Raf-1 pool. J Biol Chem 274: 35719-35724. doi:10.1074/jbc.
274.50.35719. PubMed: 10585452.
22. Lisenbee CS, Karnik SK, Trelease RN (2003) Overexpression and
mislocalization of a tail-anchored GFP redefines the identity of
peroxisomal ER. Traffic 4: 491-501. doi:10.1034/j.
1600-0854.2003.00107.x. PubMed: 12795694.
23. Griffiths WJ, Cox TM (2003) Co-localization of the mammalian
hemochromatosis gene product (HFE) and a newly identified transferrin
receptor (TfR2) in intestinal tissue and cells. J Histochem Cytochem 51:
613-624. doi:10.1177/002215540305100507. PubMed: 12704209.
24. Berggård T, Linse S, James P (2007) Methods for the detection and
analysis of protein-protein interactions. Proteomics 7: 2833-2842. doi:
10.1002/pmic.200700131. PubMed: 17640003.
25. Söderberg O, Gullberg M, Jarvius M, Ridderstråle K, Leuchowius KJ et
al. (2006) Direct observation of individual endogenous protein
complexes in situ by proximity ligation. Nat Methods 3: 995-1000. doi:
10.1038/nmeth947. PubMed: 17072308.
26. Vogt TM, Blackwell AD, Giannetti AM, Bjorkman PJ, Enns CA (2003)
Heterotypic interactions between transferrin receptor and transferrin
receptor 2. Blood 101: 2008-2014. doi:10.1182/blood-2002-09-2742.
PubMed: 12406888.
Interaction between Hemochromatosis Proteins
PLOS ONE | www.plosone.org 11 October 2013 | Volume 8 | Issue 10 | e77267
